BioCentury
ARTICLE | Emerging Company Profile

Launching with $81M, Third Rock’s Faze is latest biotech seeking to unravel biomolecular condensates biology

Emerging Company Profile: dissecting normal and pathogenic biomolecular condensate biology to enable drug development

December 11, 2020 1:34 AM UTC

Research into biomolecular condensates is gaining momentum with Third Rock launching the third company in the past month that aims to tackle the emerging space.

On Thursday, the firm launched Faze Medicines Inc. to develop therapeutics targeting the membraneless organelles, starting with preclinical programs for ALS and myotonic dystrophy type 1. ...

BCIQ Company Profiles

Third Rock Ventures